ATE390148T1 - Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker - Google Patents

Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker

Info

Publication number: ATE390148T1
Authority: AT; Austria
Prior art keywords: angiotensin; selective; pharmaceutical composition; composition containing; receptor
Prior art date: 2003-10-10

Application number

AT04766880T

Other languages

English (en)

Inventor

Dominique Baum

Gerhard-Wilhelm Bielenberg

Bernd Boedecker

Dirk Thormaehlen

Original Assignee

Solvay Pharm Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-10-10

Filing date

2004-10-07

Publication date

2008-04-15

2004-10-07 Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh

2008-04-15 Application granted granted Critical

2008-04-15 Publication of ATE390148T1 publication Critical patent/ATE390148T1/de

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 3
102000008873 Angiotensin II receptor Human genes 0.000 title abstract 2
108050000824 Angiotensin II receptor Proteins 0.000 title abstract 2
229940123749 Imidazoline receptor agonist Drugs 0.000 title 1
239000003087 receptor blocking agent Substances 0.000 title 1
206010020772 Hypertension Diseases 0.000 abstract 2
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 2
WPNJAUFVNXKLIM-UHFFFAOYSA-N Moxonidine Chemical compound COC1=NC(C)=NC(Cl)=C1NC1=NCCN1 WPNJAUFVNXKLIM-UHFFFAOYSA-N 0.000 abstract 1
229960000573 eprosartan mesylate Drugs 0.000 abstract 1
DJSLTDBPKHORNY-XMMWENQYSA-N eprosartan methanesulfonate Chemical compound CS(O)(=O)=O.C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 DJSLTDBPKHORNY-XMMWENQYSA-N 0.000 abstract 1
230000001631 hypertensive effect Effects 0.000 abstract 1
229940083183 imidazoline receptor agonists Drugs 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
229960003938 moxonidine Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT04766880T 2003-10-10 2004-10-07 Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker ATE390148T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP03103763		2003-10-10

Publications (1)

Publication Number	Publication Date
ATE390148T1 true ATE390148T1 (de)	2008-04-15

Family

ID=34486329

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT04766880T ATE390148T1 (de)	2003-10-10	2004-10-07	Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker

Country Status (19)

Country	Link
US (2)	US20050143435A1 (de)
EP (1)	EP1673107B1 (de)
JP (1)	JP4829115B2 (de)
KR (1)	KR101137084B1 (de)
CN (1)	CN100453117C (de)
AT (1)	ATE390148T1 (de)
AU (1)	AU2004283047B2 (de)
BR (1)	BRPI0415198A (de)
CA (1)	CA2541867C (de)
DE (1)	DE602004012763T2 (de)
ES (1)	ES2304624T3 (de)
IL (1)	IL174762A (de)
MX (1)	MXPA06004029A (de)
NO (1)	NO335735B1 (de)
PL (1)	PL1673107T3 (de)
RU (1)	RU2362561C2 (de)
UA (1)	UA83077C2 (de)
WO (1)	WO2005039639A2 (de)
ZA (1)	ZA200601804B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4675586B2 (ja) *	2004-06-23	2011-04-27	壽製薬株式会社	高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤
WO2007050485A2 (en) *	2005-10-25	2007-05-03	Merck & Co., Inc.	Combination of a dipeptidyl peptidase-4 inhibitor and an anti-hypertensive agent for the treatment of diabetes and hypertension
WO2007144175A2 (en)	2006-06-16	2007-12-21	Lek Pharmaceuticals D.D.	Pharmaceutical composition comprising hydrochlorothiazide and telmisartan
EP2018885B1 (de)	2007-07-25	2011-02-09	Schott forma vitrum ag	Verabreichungsvorrichtung
EP2203158A4 (de) *	2007-10-30	2012-12-26	Reddys Lab Ltd Dr	Pharmazeutische formulierungen mit telmisartan und hydrochlorthiazid
MX2011014005A (es) *	2009-06-30	2012-04-30	Sanofi Sa	Composiciones de sodis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su uso terapeutica.
CN102850331B (zh) *	2012-09-17	2015-05-20	符爱清	一种化合物的制备方法
MD4412C1 (ro) *	2014-08-29	2016-11-30	Алёна ДУРНЯ	Utilizare a acidului 4-({2-butil-5-[2-carboxi-2-(tiofen-2-ilmetil)et-1-en-1-il] -1H-imidazol-1-il}metil) benzoic pentru ameliorarea elasticităţii vasculare în profilaxia complicaţiilor de geneză hipertensivă
PL424452A1 (pl) *	2018-01-31	2019-08-12	Forty-Four Pharmaceuticals Spółka Z Ograniczoną Odpowiedzialnością	Inhibitory obojętnej endopeptydazy (NEP) i ludzkiej rozpuszczalnej endopeptydazy (hSEP) do profilaktyki i leczenia chorób oczu
RU2734281C1 (ru) *	2019-06-11	2020-10-14	Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН)	Композиция для лечения артериальной гипертензии и ассоциированных с ней патологий сердечно-сосудистой системы
EP3986412A4 (de) *	2019-06-21	2023-11-15	The Broad Institute, Inc.	Mittel zur umkehrung von toxischen proteinopathien
GB202006074D0 (en)	2020-04-24	2020-06-10	Vicore Pharma Ab	New composition
WO2025002914A1 (en)	2023-06-26	2025-01-02	Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.)	Antagonists of the imidazoline-1 receptor for use in the prevention and/or treatment of an autoinflammatory or autoimmune disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5138069A (en) *	1986-07-11	1992-08-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
US5354867A (en) *	1988-12-06	1994-10-11	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking imidazoles
US5185351A (en) *	1989-06-14	1993-02-09	Smithkline Beecham Corporation	Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
US5312828A (en) *	1989-06-14	1994-05-17	Finkelstein Joseph A	Substituted imidazoles having angiotensin II receptor blocking activity
ATE134624T1 (de) *	1990-02-19	1996-03-15	Ciba Geigy Ag	Acylverbindungen
US5270317A (en) *	1990-03-20	1993-12-14	Elf Sanofi	N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
JP2707390B2 (ja) *	1992-05-22	1998-01-28	壽製薬株式会社	シクロヘプトイミダゾ−ル誘導体及びその製造方法並びにこれを含有する薬剤
DE4423177A1 (de) *	1994-07-01	1996-01-04	Kali Chemie Pharma Gmbh	Antihyperglykämisch wirksame Arzneimittel
US5972948A (en) *	1994-07-01	1999-10-26	Solvay Pharmaceuticals Gmbh	Method of inhibiting hyperglycemia and pharmaceutical composition for use therein
ZA981029B (en) *	1997-02-11	1999-08-10	Lilly Co Eli	Pharmaceutical agents.
US20030059471A1 (en) *	1997-12-15	2003-03-27	Compton Bruce Jon	Oral delivery formulation
US6235311B1 (en) *	1998-03-18	2001-05-22	Bristol-Myers Squibb Company	Pharmaceutical composition containing a combination of a statin and aspirin and method
JP4107831B2 (ja) *	2000-11-21	2008-06-25	第一三共株式会社	医薬組成物
US20030152622A1 (en) *	2001-10-25	2003-08-14	Jenny Louie-Helm	Formulation of an erodible, gastric retentive oral diuretic
HU0200980D0 (de) *	2002-03-14	2002-05-29	Gabor S Pal Dr
AU2003268493A1 (en) *	2002-09-11	2004-04-30	Merck & Co., Inc.	Piperazine urea derivatives as melanocortin-4 receptor agonists

2004
- 2004-10-07 EP EP04766880A patent/EP1673107B1/de not_active Expired - Lifetime
- 2004-10-07 ES ES04766880T patent/ES2304624T3/es not_active Expired - Lifetime
- 2004-10-07 KR KR1020067006561A patent/KR101137084B1/ko not_active Expired - Fee Related
- 2004-10-07 AT AT04766880T patent/ATE390148T1/de not_active IP Right Cessation
- 2004-10-07 WO PCT/EP2004/052468 patent/WO2005039639A2/en not_active Ceased
- 2004-10-07 BR BRPI0415198-4A patent/BRPI0415198A/pt not_active Application Discontinuation
- 2004-10-07 RU RU2006115796/15A patent/RU2362561C2/ru active
- 2004-10-07 PL PL04766880T patent/PL1673107T3/pl unknown
- 2004-10-07 AU AU2004283047A patent/AU2004283047B2/en not_active Ceased
- 2004-10-07 ZA ZA200601804A patent/ZA200601804B/en unknown
- 2004-10-07 CA CA2541867A patent/CA2541867C/en not_active Expired - Fee Related
- 2004-10-07 DE DE602004012763T patent/DE602004012763T2/de not_active Expired - Lifetime
- 2004-10-07 MX MXPA06004029A patent/MXPA06004029A/es active IP Right Grant
- 2004-10-07 JP JP2006530280A patent/JP4829115B2/ja not_active Expired - Fee Related
- 2004-10-07 UA UAA200604846A patent/UA83077C2/ru unknown
- 2004-10-07 CN CNB2004800285299A patent/CN100453117C/zh not_active Expired - Fee Related
- 2004-10-07 US US10/959,317 patent/US20050143435A1/en not_active Abandoned
2006
- 2006-04-04 IL IL174762A patent/IL174762A/en not_active IP Right Cessation
- 2006-05-09 NO NO20062088A patent/NO335735B1/no not_active IP Right Cessation
2011
- 2011-05-26 US US13/116,620 patent/US20110229571A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CN100453117C (zh)	2009-01-21
KR20060117912A (ko)	2006-11-17
IL174762A0 (en)	2006-08-20
RU2006115796A (ru)	2007-11-27
KR101137084B1 (ko)	2012-04-24
CA2541867C (en)	2012-06-12
RU2362561C2 (ru)	2009-07-27
WO2005039639A2 (en)	2005-05-06
AU2004283047B2 (en)	2009-09-17
PL1673107T3 (pl)	2008-06-30
BRPI0415198A (pt)	2006-12-05
JP4829115B2 (ja)	2011-12-07
US20110229571A1 (en)	2011-09-22
NO335735B1 (no)	2015-02-02
DE602004012763T2 (de)	2009-05-07
US20050143435A1 (en)	2005-06-30
CN1859924A (zh)	2006-11-08
ES2304624T3 (es)	2008-10-16
WO2005039639A3 (en)	2005-08-11
CA2541867A1 (en)	2005-05-06
NO20062088L (no)	2006-07-07
EP1673107A2 (de)	2006-06-28
EP1673107B1 (de)	2008-03-26
AU2004283047A1 (en)	2005-05-06
MXPA06004029A (es)	2006-06-28
WO2005039639B1 (en)	2005-09-22
JP2007508276A (ja)	2007-04-05
IL174762A (en)	2010-11-30
HK1096293A1 (zh)	2007-06-01
ZA200601804B (en)	2007-05-30
UA83077C2 (ru)	2008-06-10
DE602004012763D1 (de)	2008-05-08

Legal Events

Date	Code	Title	Description
2008-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
UA96308C2 (ru)	2011-10-25	Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
ATE390148T1 (de)	2008-04-15	Pharmazeutische zusammensetzung mit einem selektiven i1 imidazolin-rezeptor-agonisten und einem angiotensin-ii-rezeptorblocker
WO2007136577A3 (en)	2008-01-10	Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
ATE469895T1 (de)	2010-06-15	Cgrp-rezeptorantagonisten
TW200605882A (en)	2006-02-16	Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
ECSP066468A (es)	2006-11-16	Antagonistas de receptores muscarínicos de acetilcolina
TW200607798A (en)	2006-03-01	Progesterone receptor modulators comprising pyrrole-oxindole derivatives and uses thereof
BRPI0910182A2 (pt)	2017-05-30	composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
MXPA06011924A (es)	2007-06-11	Dispositivo de liberacion continua base polimeros.
BRPI0612674B8 (pt)	2021-05-25	preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
CL2008003847A1 (es)	2009-11-27	Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad.
DK2049475T3 (da)	2012-03-05	Cyclohexyl-substituerede pyrrolidinoner som inhibitorer af 11-beta-hydroxysteroid dehydrogenase1
WO2008021851A3 (en)	2008-06-26	Novel compounds as antagonists or inverse agonists for opioid receptors
WO2004100875A3 (en)	2005-03-17	Benzimidazoles, compositions containing such compounds and methods of use
EP1993560A4 (de)	2010-06-02	Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
DE602005021494D1 (de)	2010-07-08	Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung
EP2101781A4 (de)	2010-02-10	Verfahren zur behandlung oder vorbeugung von symptomen hormoneller veränderungen
EA201001312A1 (ru)	2011-04-29	Твердая фармацевтическая композиция, содержащая непептидный антагонист рецептора ангиотензина ii и диуретик
WO2007095113A3 (en)	2008-12-11	Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
BRPI0612189A2 (pt)	2009-01-20	composto, composiÇço farmacÊutica, mÉtodo para ligar receptores opiàides
EP1549655A4 (de)	2006-05-31	Substituierte bizyklische thiophen-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren
EA200801369A1 (ru)	2009-02-27	Способы трансдермального введения агониста рецептора индолсеротонина и трансдермальные лекарственные формы для применения этого способа
CL2007003613A1 (es)	2008-07-11	Compuestos nitroderivados, antagonistas del receptor de angiotensina ii; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar hipertension.
MX2009003441A (es)	2009-10-16	Agonistas del receptor de eritropoyetina humana, composiciones, metodos y usos para prevenir o tratar condiciones relacionadas con la intolerancia a la glucosa.
MX2007004661A (es)	2007-06-22	Derivados de 1-(hetero)aril-3-amino-pirrolidina para usarse como antagonistas del receptor mglur3.